These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18335884)

  • 21. Evaluation of use of proton pump inhibitors in Greece.
    Ntaios G; Chatzinikolaou A; Kaiafa G; Savopoulos C; Hatzitolios A; Karamitsos D
    Eur J Intern Med; 2009 Mar; 20(2):171-3. PubMed ID: 19327607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy.
    Berrutti M; Pellicano R; Astegiano M; Smedile A; Saracco G; Morgando A; De Angelis C; Repici A; Fagoonee S; Leone N; Rizzetto M
    Minerva Gastroenterol Dietol; 2008 Dec; 54(4):355-8. PubMed ID: 19047976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
    Sánchez-Delgado J; Calvet X; Bujanda L; Gisbert JP; Titó L; Castro M
    Am J Gastroenterol; 2008 Sep; 103(9):2220-3. PubMed ID: 18564109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helicobacter pylori infection: a clinical overview.
    Kandulski A; Selgrad M; Malfertheiner P
    Dig Liver Dis; 2008 Aug; 40(8):619-26. PubMed ID: 18396114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Conservative management of gastroesophageal reflux and reflux esophagitis].
    Fahrländer H
    Leber Magen Darm; 1972 Feb; 2(2):54-5. PubMed ID: 5073413
    [No Abstract]   [Full Text] [Related]  

  • 26. Present and potential therapies for reflux esophagitis.
    Hogan WJ; Dodds WJ; Condon RE
    Wis Med J; 1977 Apr; 76(4):S60-2. PubMed ID: 855362
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased body mass index after H. pylori eradication for duodenal ulcer predisposes to erosive reflux esophagitis.
    Yang YJ; Sheu BS; Chang WL; Cheng HC; Yang HB
    J Clin Gastroenterol; 2009 Sep; 43(8):705-10. PubMed ID: 19398924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastroscopy in immigrants of Turkish descent.
    Wegman AI; Loffeld RJ
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1187-90. PubMed ID: 19476561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroesophageal reflux disease.
    Fernández-Fernández FJ
    N Engl J Med; 2009 Feb; 360(7):729; author reply 729-30. PubMed ID: 19222130
    [No Abstract]   [Full Text] [Related]  

  • 30. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.
    Akyildiz M; Akay S; Musoglu A; Tuncyurek M; Aydin A
    Eur J Intern Med; 2009 Jan; 20(1):53-7. PubMed ID: 19237093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What is currently the Helicobacter pylori eradication therapy of choice? Triple therapy (PPI, amoxicillin and clarithromycin) or sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and metronidazole for a further 5 days)?].
    Sánchez-Delgado J
    Gastroenterol Hepatol; 2009 Jan; 32(1):68-9. PubMed ID: 19174106
    [No Abstract]   [Full Text] [Related]  

  • 32. Effective prevention and treatment of Helicobacter pylori infection using a combination of catechins and sialic acid in AGS cells and BALB/c mice.
    Yang JC; Shun CT; Chien CT; Wang TH
    J Nutr; 2008 Nov; 138(11):2084-90. PubMed ID: 18936202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases.
    Chomvarin C; Ottiwet O; Hahnvajanawong C; Intapan PM; Wongwajana S
    Int J Infect Dis; 2009 Sep; 13(5):647-54. PubMed ID: 19233700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic identification of biomarkers related to Helicobacter pylori-associated gastroduodenal disease: challenges and opportunities.
    Wu MS; Chow LP; Lin JT; Chiou SH
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1657-61. PubMed ID: 19120858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicobacter pylori infection and antisecretory efficacy of proton-pump inhibitors in gastroesophageal reflux disease: a liaison dangereuse or an innocent interplay?
    Parente FR; Bargiggia SA; Anderloni A
    Scand J Gastroenterol; 2006 Oct; 41(10):1121-5. PubMed ID: 16990195
    [No Abstract]   [Full Text] [Related]  

  • 37. [Genetic type of Helicobacter pylori and the efficacy of eradication therapy].
    Parzecka M; Szaflarska-Popławska A; Mierzwa G; Gorzkiewicz M; Łuczak S; Grzybowski T
    Pol Merkur Lekarski; 2009 Feb; 26(152):105-9. PubMed ID: 19388513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Helicobacter pylori and non-malignant diseases.
    Shirin H; Leja M; Niv Y
    Helicobacter; 2008 Oct; 13 Suppl 1():23-7. PubMed ID: 18783518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving issues in the management of reflux disease?
    Yuan Y; Hunt RH
    Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A screen-and-treat policy for Helicobacter pylori in Western Europe is affordable and would be effective.
    Axon A
    Helicobacter; 2008 Aug; 13(4):231-3. PubMed ID: 18665929
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.